These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9091474)

  • 41. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
    Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
    Koo J
    Br J Dermatol; 1998 Jul; 139(1):88-95. PubMed ID: 9764154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial.
    Kumar R; Dogra S; Amarji B; Singh B; Kumar S; Sharma ; Vinay K; Mahajan R; Katare OP
    JAMA Dermatol; 2016 Jul; 152(7):807-15. PubMed ID: 27096709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atorvastatin for the treatment of plaque-type psoriasis.
    Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
    Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
    Papp K; Bissonnette R; Rosoph L; Wasel N; Lynde CW; Searles G; Shear NH; Huizinga RB; Maksymowych WP
    Lancet; 2008 Apr; 371(9621):1337-42. PubMed ID: 18424323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.
    Faerber L; Braeutigam M; Weidinger G; Mrowietz U; Christophers E; Schulze HJ; Mahrle G; Meffert H; Drechsler S
    Am J Clin Dermatol; 2001; 2(1):41-7. PubMed ID: 11702620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis.
    Jan V; Vaillant L; Bressieux JM; Barthélemy H; Legoux A; Steiner HG; Reigneau O
    Eur J Dermatol; 1999 Dec; 9(8):615-7. PubMed ID: 10586127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.
    Kokelj F; Torsello P; Plozzer C
    J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):143-6. PubMed ID: 9553911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
    Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
    J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined clinical, capillaroscopic and ultrasound evaluation during treatment of plaque psoriasis with oral cyclosporine.
    Musumeci ML; Lacarrubba F; Fusto CM; Micali G
    Int J Immunopathol Pharmacol; 2013; 26(4):1027-33. PubMed ID: 24355242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis.
    Di Lernia V; Stingeni L; Boccaletti V; Calzavara Pinton PG; Guarneri C; Belloni Fortina A; Panzone M; Corazza M; Neri I; Cambiaghi S; Lasagni C; Ficarelli E; Gisondi P
    J Dermatolog Treat; 2016 Oct; 27(5):395-8. PubMed ID: 26571044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
    Dermatology; 1993; 187 Suppl 1():30-7. PubMed ID: 8369577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis.
    Kim WU; Cho ML; Kim SI; Yoo WH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
    J Rheumatol; 2000 Feb; 27(2):324-31. PubMed ID: 10685792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
    N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of psoriasis with cyclosporin. Experience at Johannesburg Hospital.
    Nevin RJ; Schulz EJ
    S Afr Med J; 1995 Nov; 85(11):1165-8. PubMed ID: 8597006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term safety of cyclosporine in the treatment of psoriasis.
    Grossman RM; Chevret S; Abi-Rached J; Blanchet F; Dubertret L
    Arch Dermatol; 1996 Jun; 132(6):623-9. PubMed ID: 8651712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.